<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/165691B8-AFD5-48DE-89CC-512CE600302C"><gtr:id>165691B8-AFD5-48DE-89CC-512CE600302C</gtr:id><gtr:firstName>Herbie</gtr:firstName><gtr:surname>Newell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_G0902167"><gtr:id>C8AECD95-A19B-460C-AFCF-0E5B8923EF40</gtr:id><gtr:title>MRC Contribution to a CR-UK and EPSRC Cancer Imaging Initiative</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_G0902167</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Medical Research Council (MRC) is investing #3 million in a nationwide initiative to improve the detection, diagnosis and treatment of cancer. The #50 million initiative, in partnership with Cancer Research UK (CRUK), the Engineering Physical Sciences Research Council and the National Institute for Health Research, will help experts develop new techniques and uses for existing cancer imaging technologies. The MRCs investment is part of the organisations broader, long-term plans to inject funds into imaging and translational research and will help put the UK on track to lead the world in imaging research|</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>3000000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bath</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Univeristy of Durham</gtr:description><gtr:id>B76C5AE1-3E3B-43B2-BF88-E491F0B8166B</gtr:id><gtr:impact>See publications</gtr:impact><gtr:outcomeId>VAM1yaCiqYm-1</gtr:outcomeId><gtr:partnerContribution>Joint grantee</gtr:partnerContribution><gtr:piContribution>Joint grantee on Programme</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Interaction with pharma and biotech</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>58B6F6CA-9442-4A37-AEA2-6BE40ECF62D4</gtr:id><gtr:impact>Contacts with numerous pharma and boitech employees

Clinical trials on novel agents with imaging endpoints brought to Newcastle</gtr:impact><gtr:outcomeId>bhNTzFWxQzK</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Dementia Platform</gtr:description><gtr:end>2016-11-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>63C4B669-8DB0-41E3-BB16-8B9620716704</gtr:id><gtr:outcomeId>56cec4741f1e06.89788662</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC CASE PhD Studentship</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3016B1D8-AA5F-4953-832B-B079BD0DD94F</gtr:id><gtr:outcomeId>VFFFFwRyNM40</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>66B5AD80-A3C9-420A-9F01-87395BF37575</gtr:id><gtr:title>Design principles and theory of paramagnetic fluorine-labelled lanthanide complexes as probes for (19)F magnetic resonance: a proof-of-concept study.</gtr:title><gtr:parentPublicationTitle>Chemistry (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/470904b70b5da14c4b918058a2920d6b"><gtr:id>470904b70b5da14c4b918058a2920d6b</gtr:id><gtr:otherNames>Chalmers KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0947-6539</gtr:issn><gtr:outcomeId>fGN7HFRf1dD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>900CF506-B830-4A4A-B045-F504D7046F83</gtr:id><gtr:title>THE FIRST SINGLE-STEP-SINGLE-POST SYNTHESIS OF 4-[F-18]SFB</gtr:title><gtr:parentPublicationTitle>JOURNAL OF LABELLED COMPOUNDS &amp; RADIOPHARMACEUTICALS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6375fb0d4579218eafc36e32d39c1574"><gtr:id>6375fb0d4579218eafc36e32d39c1574</gtr:id><gtr:otherNames>Yan Ran</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0362-4803</gtr:issn><gtr:outcomeId>HPTJ1ezLTw2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14FFE4D6-BB83-4025-9DE3-E1111281F6E4</gtr:id><gtr:title>Pharmacologic biomarkers in the development of stratified cancer medicine.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6da4e403477252ccc653beb527c1848"><gtr:id>e6da4e403477252ccc653beb527c1848</gtr:id><gtr:otherNames>Figg WD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>545ca929a5fdc2.10173265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27BFA6DF-E027-40C8-950B-EFEE8B66BCF8</gtr:id><gtr:title>THE FIRST SYNTHESIS OF ETHYL 3-[F-18]FLUOROBENZOATE USING [F-18]FLUORIDE</gtr:title><gtr:parentPublicationTitle>JOURNAL OF LABELLED COMPOUNDS &amp; RADIOPHARMACEUTICALS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6375fb0d4579218eafc36e32d39c1574"><gtr:id>6375fb0d4579218eafc36e32d39c1574</gtr:id><gtr:otherNames>Yan Ran</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0362-4803</gtr:issn><gtr:outcomeId>LhLhjNLdCjy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>414F751B-EB96-4732-806A-49B7B313FAA0</gtr:id><gtr:title>The first preparation of all regioisomers of ethyl [(18)f]fluorobenzoates</gtr:title><gtr:parentPublicationTitle>JOURNAL OF LABELLED COMPOUNDS &amp; RADIOPHARMACEUTICALS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6375fb0d4579218eafc36e32d39c1574"><gtr:id>6375fb0d4579218eafc36e32d39c1574</gtr:id><gtr:otherNames>Yan Ran</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0362-4803</gtr:issn><gtr:outcomeId>NHJuvf1fCq7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7DFC40F-208F-40C3-BFAF-FB5EA5243583</gtr:id><gtr:title>Strategies to enhance signal intensity with paramagnetic fluorine-labelled lanthanide complexes as probes for 19F magnetic resonance.</gtr:title><gtr:parentPublicationTitle>Dalton transactions (Cambridge, England : 2003)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/470904b70b5da14c4b918058a2920d6b"><gtr:id>470904b70b5da14c4b918058a2920d6b</gtr:id><gtr:otherNames>Chalmers KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1477-9226</gtr:issn><gtr:outcomeId>doi_53d02d02d1f58ee5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F302E20-26A4-4735-BF8B-DCF5C60AB135</gtr:id><gtr:title>The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ce5f98d82646a9144cbaee2b3f2c674"><gtr:id>7ce5f98d82646a9144cbaee2b3f2c674</gtr:id><gtr:otherNames>Haagensen EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545ca929d0a9b9.26460372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75446096-EC25-43AE-84A6-48E57BC98A1C</gtr:id><gtr:title>19F-lanthanide complexes with increased sensitivity for 19F-MRI: optimization of the MR acquisition.</gtr:title><gtr:parentPublicationTitle>Magnetic resonance in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/470904b70b5da14c4b918058a2920d6b"><gtr:id>470904b70b5da14c4b918058a2920d6b</gtr:id><gtr:otherNames>Chalmers KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0740-3194</gtr:issn><gtr:outcomeId>DKyM5YPoan6</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_G0902167</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>